AIM2-inflammasome role in systemic lupus erythematous and rheumatoid arthritis

References

• Hornung V, Ablasser A, Charrel-Dennis M, et al. AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC. Nature. 2009;458(7237):514–518.
   PubMed Web of Science ®Google Scholar
• Jin T, Perry A, Jiang J, et al. Structures of the HIN domain:DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor. Immunity. 2012;36(4):561–571.
   PubMed Web of Science ®Google Scholar
• Masumoto J, Taniguchi S, Sagara J. Pyrin N-terminal homology domain- and caspase recruitment domain-dependent oligomerization of ASC. Biochem Biophys Res Commun. 2001; 280(3):652–655.
   PubMedGoogle Scholar
• Masumoto J, Taniguchi S, Ayukawa K, et al. ASC, a novel 22-kDa protein, aggregates during apoptosis of human promyelocytic leukemia HL-60 cells. J Biol Chem. 1999;274(48):33835–33838.
   PubMedGoogle Scholar
• Broz P, von Moltke J, Jones JW, et al. Differential requirement for caspase-1 autoproteolysis in pathogen-induced cell death and cytokine processing. Cell Host Microbe. 2010;8(6):471–483.
   PubMed Web of Science ®Google Scholar
• Broz P, Newton K, Lamkanfi M, et al. Redundant roles for inflammasome receptors NLRP3 and NLRC4 in host defense against Salmonella. J Exp Med. 2010;207(8):1745–1755.
   PubMed Web of Science ®Google Scholar
• Richards N, Schaner P, Diaz A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem. 2001;276(42):39320–39329.
   PubMed Web of Science ®Google Scholar
• Fernandes-Alnemri T, Wu J, Yu JW, et al. The pyroptosome: a supramolecular assembly of ASC dimers mediating inflammatory cell death via caspase-1 activation. Cell Death Differ. 2007;14(9):1590–1604.
   PubMed Web of Science ®Google Scholar
• Wickliffe KE, Leppla SH, Moayeri M. Killing of macrophages by anthrax lethal toxin: involvement of the N-end rule pathway. Cell Microbiol. 2008;10(6):1352–1362.
   PubMedGoogle Scholar
• Miao EA, Rajan JV, Aderem A. Caspase-1-induced pyroptotic cell death. Immunol Rev. 2011;243(1):206–214.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol. 2009;27:519–550.
   PubMed Web of Science ®Google Scholar
• Lamkanfi M, Kalai M, Saelens X, et al. Caspase-1 activates nuclear factor of the kappa-enhancer in B cells independently of its enzymatic activity. J Biol Chem. 2004;279(23):24785–24793.
   PubMed Web of Science ®Google Scholar
• Maliszewski CR, Sato TA, Bos V, et al. Cytokine receptors and B cell functions. I. Recombinant soluble receptors specifically inhibit IL-1- and IL-4-induced B cell activities in vitro. J Immunol. 1990;144(8):3028–3033.
   PubMedGoogle Scholar
• Ben-Sasson SZ, Hu-Li J, Quiel J, et al. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A. 2009;106(17):7119–7124.
   PubMed Web of Science ®Google Scholar
• Hata H, Yoshimoto T, Hayashi N, et al. IL-18 together with anti-CD3 antibody induces human Th1 cells to produce Th1- and Th2-cytokines and IL-8. Int Immunol. 2004;16(12):1733–1739.
   PubMedGoogle Scholar
• Guo L, Wei G, Zhu J, et al. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells. Proc Natl Acad Sci U S A. 2009; 106(32):13463–13468.
   PubMed Web of Science ®Google Scholar
• Chung Y, Chang SH, Martinez GJ, et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. 17. Immunity. 2009;30(4):576–587.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6):2095–2147.
   PubMed Web of Science ®Google Scholar
• Pien GC, Biron CA. Compartmental differences in NK cell responsiveness to IL-12 during lymphocytic choriomeningitis virus infection. J Immunol. 2000;164(2):994–1001.
   PubMedGoogle Scholar
• Fink SL, Cookson BT. Caspase-1-dependent pore formation during pyroptosis leads to osmotic lysis of infected host macrophages. Cell Microbiol. 2006;8(11):1812–1825.
   PubMed Web of Science ®Google Scholar
• Fink SL, Bergsbaken T, Cookson BT. Anthrax lethal toxin and Salmonella elicit the common cell death pathway of caspase-1-dependent pyroptosis via distinct mechanisms. Proc Natl Acad Sci U S A. 2008;105(11):4312–4317.
   PubMed Web of Science ®Google Scholar
• Edgeworth JD, Spencer J, Phalipon A, et al. Cytotoxicity and interleukin-1beta processing following Shigella flexneri infection of human monocyte-derived dendritic cells. Eur J Immunol. 2002;32(5):1464–1471.
   PubMedGoogle Scholar
• Miao EA, Leaf IA, Treuting PM, et al. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat Immunol. 2010;11(12):1136–1142.
   PubMed Web of Science ®Google Scholar
• Feldmeyer L, Keller M, Niklaus G, et al. The inflammasome mediates UVB-induced activation and secretion of interleukin-1beta by keratinocytes. Curr Biol. 2007;17(13):1140–1145.
   PubMed Web of Science ®Google Scholar
• Man SM, Karki R, Sasai M, et al. IRGB10 liberates bacterial ligands for sensing by the AIM2 and caspase-11-NLRP3 inflammasomes. Cell. 2016;167(2):382–396 e17.
   PubMed Web of Science ®Google Scholar
• Sauer JD, Witte CE, Zemansky J, et al. Listeria monocytogenes triggers AIM2-mediated pyroptosis upon infrequent bacteriolysis in the macrophage cytosol. Cell Host Microbe. 2010;7(5):412–419.
   PubMed Web of Science ®Google Scholar
• Torii Y, Kawada JI, Murata T, et al. Epstein-Barr virus infection-induced inflammasome activation in human monocytes. PLoS One. 2017;12(4):e0175053.
   PubMedGoogle Scholar
• Reinholz M, Kawakami Y, Salzer S, et al. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res. 2013;305(8):723–732.
   PubMedGoogle Scholar
• Schattgen SA, Gao G, Kurt-Jones EA, et al. Cutting edge: DNA in the lung microenvironment during influenza virus infection tempers inflammation by engaging the DNA sensor AIM2. J Immunol. 2016; 196(1):29–33.
   PubMedGoogle Scholar
• Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011; 12(3):222–230.
   PubMed Web of Science ®Google Scholar
• Kim J, Gupta R, Blanco LP, et al. VDAC oligomers form mitochondrial pores to release mtDNA fragments and promote lupus-like disease. Science. 2019;366(6472):1531–1536.
   PubMed Web of Science ®Google Scholar
• Lian Q, Xu J, Yan S, et al. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2 inflammasome activation. Cell Res. 2017;27(6):784–800.
   PubMedGoogle Scholar
• Di Micco A, Frera G, Lugrin J, et al. AIM2 Inflammasome is activated by pharmacological disruption of nuclear envelope integrity. Proc Natl Acad Sci U S A. 2016;113(32):E4671-80.
   Google Scholar
• Hu B, Jin C, Li HB, et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science. 2016;354(6313):765–768.
   PubMed Web of Science ®Google Scholar
• DeYoung KL, Ray ME, Su YA, et al. Cloning a novel member of the human interferon-inducible gene family associated with control of tumorigenicity in a model of human melanoma. Oncogene. 1997;15(4):453–457.
   PubMed Web of Science ®Google Scholar
• Panchanathan R, Duan X, Arumugam M, et al. Cell type and gender-dependent differential regulation of the p202 and Aim2 proteins: implications for the regulation of innate immune responses in SLE. Mol Immunol. 2011;49(1–2):273–280.
   PubMedGoogle Scholar
• Choubey D, Duan X, Dickerson E, et al. Interferon-inducible p200-family proteins as novel sensors of cytoplasmic DNA: role in inflammation and autoimmunity. J Interferon Cytokine Res. 2010;30(6):371–380.
   PubMedGoogle Scholar
• Sampson TR, Napier BA, Schroeder MR, et al. A CRISPR-Cas system enhances envelope integrity mediating antibiotic resistance and inflammasome evasion. Proc Natl Acad Sci U S A. 2014;111(30):11163–11168.
   PubMed Web of Science ®Google Scholar
• Ge J, Gong YN, Xu Y, et al. Preventing bacterial DNA release and absent in melanoma 2 inflammasome activation by a legionella effector functioning in membrane trafficking. Proc Natl Acad Sci U S A. 2012;109(16):6193–6198.
   PubMedGoogle Scholar
• Khare S, Ratsimandresy RA, de Almeida L, et al. The PYRIN domain-only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA viruses. Nat Immunol. 2014;15(4):343–353.
   PubMedGoogle Scholar
• Yin Q, Sester DP, Tian Y, et al. Molecular mechanism for p202-mediated specific inhibition of AIM2 inflammasome activation. Cell Rep. 2013;4(2):327–339.
   PubMedGoogle Scholar
• Roberts TL, Idris A, Dunn JA, et al. HIN-200 proteins regulate caspase activation in response to foreign cytoplasmic DNA. Science. 2009;323(5917):1057–1060.
   PubMedGoogle Scholar
• Wang PH, Ye ZW, Deng JJ, et al. Inhibition of AIM2 inflammasome activation by a novel transcript isoform of IFI16. EMBO Rep. 2018;19(10):e45737.
   Google Scholar
• Veeranki S, Duan X, Panchanathan R, et al. IFI16 protein mediates the anti-inflammatory actions of the type-I interferons through suppression of activation of caspase-1 by inflammasomes. PLoS One. 2011;6(10):e27040.
   PubMed Web of Science ®Google Scholar
• Liu T, Tang Q, Liu K, et al. TRIM11 suppresses AIM2 inflammasome by degrading AIM2 via p62-dependent selective autophagy. Cell Rep. 2016;16(7):1988–2002.
   PubMedGoogle Scholar
• Duan X, Ponomareva L, Veeranki S, et al. Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol Cancer Res. 2011;9(5):589–602.
   PubMedGoogle Scholar
• Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179(4):1317–1330.
   PubMed Web of Science ®Google Scholar
• Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol. 2011;187(1):538–552.
   PubMed Web of Science ®Google Scholar
• Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A. 2010;107(21):9813–9818.
   PubMed Web of Science ®Google Scholar
• Huang WN, Tso TK, Wu HC, et al. Impaired phagocytosis of apoptotic cell material in serologically active clinically quiescent patients with systemic lupus erythematosis. Int J Rheum Dis. 2016;19(12):1310–1316.
   PubMedGoogle Scholar
• Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum. 2010;39(6):491–503.
   PubMed Web of Science ®Google Scholar
• Salvi V, Gianello V, Busatto S, et al. Exosome-delivered microRNAs promote IFN-alpha secretion by human plasmacytoid DCs via TLR7. JCI Insight. 2018;3(10):e98204.
   PubMed Web of Science ®Google Scholar
• Lee JY, Park JK, Lee EY, et al. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther. 2016;18(1):264.
   PubMedGoogle Scholar
• Fernandez DR, Telarico T, Bonilla E, et al. Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol. 2009;182(4):2063–2073.
   PubMed Web of Science ®Google Scholar
• Bave U, Magnusson M, Eloranta ML, et al. Fc gamma RIIa is expressed on natural IFN-alpha-producing cells (plasmacytoid dendritic cells) and is required for the IFN-alpha production induced by apoptotic cells combined with lupus IgG. J Immunol. 2003;171(6):3296–3302.
   PubMedGoogle Scholar
• Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 2001;294(5546):1540–1543.
   PubMed Web of Science ®Google Scholar
• Blanco P, Pitard V, Viallard JF, et al. Increase in activated CD8+ T lymphocytes expressing perforin and granzyme B correlates with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(1):201–211.
   PubMedGoogle Scholar
• Jego G, Palucka AK, Blanck JP, et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity. 2003;19(2):225–234.
   PubMed Web of Science ®Google Scholar
• Stricker M, Reny A. 615 cases of orbital fractures. Ann Chir Plast. 1969;14(2):127–132.
   PubMedGoogle Scholar
• Choubey D, Panchanathan R. Interferon-inducible Ifi200-family genes in systemic lupus erythematosus. Immunol Lett. 2008;119(1–2):32–41.
   PubMedGoogle Scholar
• Caneparo V, Cena T, De Andrea M, et al. Anti-IFI16 antibodies and their relation to disease characteristics in systemic lupus erythematosus. Lupus. 2013;22(6):607–613.
   PubMedGoogle Scholar
• Navratil JS, Ahearn JM. Apoptosis, clearance mechanisms, and the development of systemic lupus erythematosus. Curr Rheumatol Rep. 2001;3(3):191–198.
   PubMedGoogle Scholar
• Fan H, Longacre A, Meng F, et al. Cytokine dysregulation induced by apoptotic cells is a shared characteristic of macrophages from nonobese diabetic and systemic lupus erythematosus-prone mice. J Immunol. 2004;172(8):4834–4843.
   PubMedGoogle Scholar
• Fairhurst AM, Xie C, Fu Y, et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol. 2009;183(10):6831–6838.
   PubMedGoogle Scholar
• Bethunaickan R, Berthier CC, Ramanujam M, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol. 2011;186(8):4994–5003.
   PubMed Web of Science ®Google Scholar
• Triantafyllopoulou A, Franzke CW, Seshan SV, et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A. 2010;107(7):3012–3017.
   PubMedGoogle Scholar
• Qiao B, Wu J, Chu YW, et al. Induction of systemic lupus erythematosus-like syndrome in syngeneic mice by immunization with activated lymphocyte-derived DNA. Rheumatology (Oxford). 2005;44(9):1108–1114.
   PubMed Web of Science ®Google Scholar
• Zhang W, Cai Y, Xu W, et al. AIM2 facilitates the apoptotic DNA-induced systemic lupus erythematosus via arbitrating macrophage functional maturation. J Clin Immunol. 2013;33(5):925–937.
   PubMed Web of Science ®Google Scholar
• Kimkong I, Avihingsanon Y, Hirankarn N. Expression profile of HIN200 in leukocytes and renal biopsy of SLE patients by real-time RT-PCR. Lupus. 2009;18(12):1066–1072.
   PubMedGoogle Scholar
• Kayki-Mutlu G, Aksoyalp ZS, Wojnowski L, et al. A year in pharmacology: new drugs approved by the US food and drug administration in 2021. Naunyn Schmiedebergs Arch Pharmacol. 2022;395(8):867–885.
   PubMedGoogle Scholar
• Levy RA, Gonzalez-Rivera T, Khamashta M, et al. 10 years of belimumab experience: What have we learnt? Lupus. 2021;30(11):1705–1721.
   PubMedGoogle Scholar
• Westphal HJ, Kaben U. In vitro effect of UVA/UVB and PUVA on the undirected migration of polymorphonuclear granulocytes. Dermatol Monatsschr. 1987;173(6):316–322.
   PubMedGoogle Scholar
• Jayne D, Rovin B, Mysler EF, et al. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis. 2022;81(4):496–506.
   PubMedGoogle Scholar
• Calvani N, Tucci M, Richards HB, et al. Th1 cytokines in the pathogenesis of lupus nephritis: the role of IL-18. Autoimmun Rev. 2005;4(8):542–548.
   PubMed Web of Science ®Google Scholar
• Ostendorf B, Iking-Konert C, Kurz K, et al. Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis. Ann Rheum Dis. 2005;64(4):630–633.
   PubMed Web of Science ®Google Scholar
• Yang CA, Huang ST, Chiang BL. Sex-dependent differential activation of NLRP3 and AIM2 inflammasomes in SLE macrophages. Rheumatology (Oxford). 2015;54(2):324–331.
   PubMed Web of Science ®Google Scholar
• Kato Y, Park J, Takamatsu H, et al. Apoptosis-derived membrane vesicles drive the cGAS-STING pathway and enhance type I IFN production in systemic lupus erythematosus. Ann Rheum Dis. 2018;77(10):1507–1515.
   PubMed Web of Science ®Google Scholar
• Zhang J, Jacobi AM, Mackay M, et al. Identification of DNA-reactive B cells in patients with systemic lupus erythematosus. J Immunol Methods. 2008;338(1–2):79–84.
   PubMedGoogle Scholar
• Ma K, Du W, Wang X, et al. Multiple functions of B cells in the pathogenesis of systemic lupus erythematosus. Int J Mol Sci. 2019;20(23):6021.
   Google Scholar
• Appel GB. Immune-complex glomerulonephritis–deposits plus interest. N Engl J Med. 1993;328(7):505–506.
   PubMedGoogle Scholar
• Poppelaars F, Thurman JM. Complement-mediated kidney diseases. Mol Immunol. 2020;128:175–187.
   PubMedGoogle Scholar
• Fujinaka H, Yamamoto T, Feng L, et al. Anti-perforin antibody treatment ameliorates experimental crescentic glomerulonephritis in WKY rats. Kidney Int. 2007;72(7):823–830.
   PubMedGoogle Scholar
• Reynolds J, Norgan VA, Bhambra U, et al. Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J Am Soc Nephrol. 2002;13(2):359–369.
   PubMedGoogle Scholar
• Neumann E, Hasseli R, Lange U, et al. The role of extracellular nucleic acids in rheumatoid arthritis. Curr Pharm Biotechnol. 2018;19(15):1182–1188.
   PubMed Web of Science ®Google Scholar
• Wehr P, Purvis H, Law SC, et al. Dendritic cells, T cells and their interaction in rheumatoid arthritis. Clin Exp Immunol. 2019;196(1):12–27.
   PubMed Web of Science ®Google Scholar
• Hajizadeh S, DeGroot J, TeKoppele JM, et al. Extracellular mitochondrial DNA and oxidatively damaged DNA in synovial fluid of patients with rheumatoid arthritis. Arthritis Res Ther. 2003;5(5):R234-40.
   PubMedGoogle Scholar
• Bakele M, Joos M, Burdi S, et al. Localization and functionality of the inflammasome in neutrophils. J Biol Chem. 2014;289(8):5320–5329.
   PubMedGoogle Scholar
• Rossol M, Kraus S, Pierer M, et al. The CD14(bright) CD16+ monocyte subset is expanded in rheumatoid arthritis and promotes expansion of the Th17 cell population. Arthritis Rheum. 2012;64(3):671–677.
   PubMedGoogle Scholar
• Kawanaka N, Yamamura M, Aita T, et al. CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. Arthritis Rheum. 2002;46(10):2578–2586.
   PubMedGoogle Scholar
• Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(8):472–485.
   PubMed Web of Science ®Google Scholar
• Jakobs C, Perner S, Hornung V. AIM2 drives joint inflammation in a self-DNA triggered model of chronic polyarthritis. PLoS One. 2015;10(6):e0131702.
   PubMedGoogle Scholar
• Chen Y, Fujuan Q, Chen E, et al. Expression of AIM2 in rheumatoid arthritis and its role on Fibroblast-Like synoviocytes. Mediators Inflamm. 2020;2020:1693730.
   PubMedGoogle Scholar
• Kissel T, Reijm S, Slot LM, et al. Antibodies and B cells recognising citrullinated proteins display a broad cross-reactivity towards other post-translational modifications. Ann Rheum Dis. 2020;79(4):472–480.
   PubMed Web of Science ®Google Scholar
• Pone EJ, Zhang J, Mai T, et al. BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF-kappaB pathway. Nat Commun. 2012;3:767.
   PubMed Web of Science ®Google Scholar
• Herlands RA, Christensen SR, Sweet RA, et al. T cell-independent and toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity. 2008;29(2):249–260.
   PubMedGoogle Scholar
• Dolhain RJ, van der Heiden AN, ter Haar NT, et al. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996;39(12):1961–1969.
   PubMedGoogle Scholar
• Miltenburg AM, van Laar JM, de Kuiper R, et al. T cells cloned from human rheumatoid synovial membrane functionally represent the Th1 subset. Scand J Immunol. 1992;35(5):603–610.
   PubMedGoogle Scholar
• Ponchel F, Goeb V, Parmar R, et al. An immunological biomarker to predict MTX response in early RA. Ann Rheum Dis. 2014;73(11):2047–2053.
   PubMedGoogle Scholar
• Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402(6759):304–309.
   PubMed Web of Science ®Google Scholar
• Wong BR, Josien R, Lee SY, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med. 1997;186(12):2075–2080.
   PubMed Web of Science ®Google Scholar
• Bosello S, Youinou P, Daridon C, et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol. 2008;35(7):1256–1264.
   PubMedGoogle Scholar
• Manzo A, Bombardieri M, Humby F, et al. Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling. Immunol Rev. 2010;233(1):267–285.
   PubMedGoogle Scholar
• Gierut A, Perlman H, Pope RM. Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am. 2010;36(2):271–296.
   PubMedGoogle Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003;423(6937):356–361.
   PubMed Web of Science ®Google Scholar
• Joosten LA, Helsen MM, Saxne T, et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol. 1999;163(9):5049–5055.
   PubMed Web of Science ®Google Scholar
• Alten R, Gram H, Joosten LA, et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(3):R67.
   PubMed Web of Science ®Google Scholar
• Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheumat. 1998;41(12):2196–2204.
   PubMed Web of Science ®Google Scholar
• Li WC, Bai L, Xu Y, et al. Identification of differentially expressed genes in synovial tissue of rheumatoid arthritis and osteoarthritis in patients. J Cell Biochem. 2019;120(3):4533–4544.
   PubMedGoogle Scholar
• Mendez-Frausto G, Medina-Rosales MN, Uresti-Rivera EE, et al. Expression and activity of AIM2-inflammasome in rheumatoid arthritis patients. Immunobiology. 2020;225(2):151880.
   PubMedGoogle Scholar
• Bustamante MF, Garcia-Carbonell R, Whisenant KD, et al. Fibroblast-like synoviocyte metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017;19(1):110.
   PubMedGoogle Scholar
• Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol. 2013;9(1):24–33.
   PubMed Web of Science ®Google Scholar
• Papagoras C, Drosos AA. A biologic immune modulator for rheumatoid arthritis. Expert Opin Biol Ther. 2011;11(8):1113–1129.
   PubMed Web of Science ®Google Scholar
• Zhao S, Chadwick L, Mysler E, et al. Review of biosimilar trials and data on adalimumab in rheumatoid arthritis. Curr Rheumatol Rep. 2018;20(10):57.
   PubMed Web of Science ®Google Scholar
• Narazaki M, Tanaka T, Kishimoto T. The role and therapeutic targeting of IL-6 in rheumatoid arthritis. Expert Rev Clin Immunol. 2017;13(6):535–551.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679–707.
   PubMed Web of Science ®Google Scholar
• Zisapel M, Paran D, Elkayam O. Rituximab in rheumatoid arthritis – therapeutic aspects based on 18 years of global experience]. Harefuah. 2019;158(9):595–600.
   PubMedGoogle Scholar